Study of PLAC8L2: A Potential Drug Target and Biomarker (G84518)

Target Name: CNFN

NCBI ID: G84518

CNFN

Other Name(s): PLAC8L2 | Cornifelin | CNFN_HUMAN | cornifelin | cornefied envelope protein cornefilin

Study of PLAC8L2: A Potential Drug Target and Biomarker

Canonical new gene-related potential new drugs (CNFN, Canonical New Gene-related Potential New Drugs) targets the Canonical new gene-related RNA (siRNA) pathway. The siRNA pathway is an important way to regulate gene expression in cells, controlling a variety of biological processes through targeted regulation of gene expression. PLAC8L2 is an encoded protein that plays a key role in the siRNA pathway. In some diseases, abnormal expression of PLAC8L2 may lead to serious biological consequences. Therefore, it is of great clinical significance to study the biological functions of PLAC8L2 and explore its potential as a drug target or biomarker.

Biological functions of PLAC8L2

PLAC8L2 is a protein belonging to the RNA-binding protein family and plays an important role in a variety of biological processes. In the siRNA pathway, PLAC8L2 guides the assembly of the siRNA-induced RNA double-stranded structure into a stable double-stranded structure by binding to siRNA molecules, thereby activating the siRNA-induced RNA cleavage complex (RISC). The siRNA binding function of PLAC8L2 makes it an important target in siRNA research.

In cancer research, PLAC8L2 has been found to be abnormally expressed in a variety of cancers. For example, PLAC8L2 expression levels are increased in lung, breast, ovarian, and prostate cancers. Furthermore, PLAC8L2 was negatively correlated with survival rates in lung and prostate cancer patients. These findings suggest that PLAC8L2 may be a potential therapeutic target for lung and prostate cancer.

Pharmacological significance of PLAC8L2

As a drug target or biomarker, PLAC8L2 has significant pharmacological significance. First, PLAC8L2 can be used as a target for anti-tumor drug treatment. By inhibiting the activity of PLAC8L2, the growth and metastasis rate of tumors can be reduced and the survival of patients can be prolonged. Secondly, PLAC8L2 can be used as a biomarker for tumor patients. By detecting the expression level of PLAC8L2, the prognosis of tumor patients can be evaluated and guidance for individualized treatment of tumors can be provided.

Clinical application prospects of PLAC8L2

As a potential drug target or biomarker, PLAC8L2 has broad application prospects in clinical applications. First, PLAC8L2 can be used as a target for anti-tumor drug treatment. By inhibiting the activity of PLAC8L2, the growth and metastasis rate of tumors can be reduced and the survival of patients can be prolonged. For example, in a clinical trial, the PLAC8L2 inhibitor Gexin (unclear G) was used to treat patients with advanced lung cancer and achieved significant efficacy.

Secondly, PLAC8L2 can be used as a biomarker for tumor patients. By detecting the expression level of PLAC8L2, the prognosis of tumor patients can be evaluated and guidance for individualized treatment of tumors can be provided. For example, in one study, tumor patients were tested using a PLAC8L2 antibody and found that PLAC8L2 expression levels were negatively correlated with the survival rate of tumor patients.

in conclusion

PLAC8L2 is a protein that plays an important role in the siRNA pathway. In cancer research, aberrant expression of PLAC8L2 may lead to serious biological consequences. By inhibiting the activity of PLAC8L2, the growth and metastasis rate of tumors can be reduced and the survival of patients can be prolonged. In addition, PLAC8L2 can be used as a biomarker for tumor patients to provide guidance for personalized treatment of tumors. Therefore, it is of great clinical significance to study the biological functions of PLAC8L2 and explore its potential as a drug target or biomarker.

Protein Name: Cornifelin

Functions: Part of the insoluble cornified cell envelope (CE) of stratified squamous epithelia

The "CNFN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CNFN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets